A detailed history of Center For Financial Planning, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Center For Financial Planning, Inc. holds 750 shares of AMGN stock, worth $198,367. This represents 0.03% of its overall portfolio holdings.

Number of Shares
750
Previous 802 6.48%
Holding current value
$198,367
Previous $250,000 3.6%
% of portfolio
0.03%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$309.38 - $337.38 $16,087 - $17,543
-52 Reduced 6.48%
750 $241,000
Q2 2024

Jul 18, 2024

SELL
$262.75 - $319.31 $12,874 - $15,646
-49 Reduced 5.76%
802 $250,000
Q1 2024

Apr 25, 2024

BUY
$268.87 - $324.56 $13,174 - $15,903
49 Added 6.11%
851 $241,000
Q4 2023

Jan 29, 2024

BUY
$255.7 - $288.46 $13,296 - $14,999
52 Added 6.93%
802 $230,000
Q1 2022

May 03, 2022

SELL
$219.27 - $242.57 $6,578 - $7,277
-30 Reduced 3.85%
750 $181,000
Q3 2021

Oct 27, 2021

SELL
$212.27 - $248.7 $165,146 - $193,488
-778 Reduced 49.94%
780 $166,000
Q2 2021

Jul 29, 2021

SELL
$233.58 - $259.14 $10,277 - $11,402
-44 Reduced 2.75%
1,558 $380,000
Q1 2021

May 10, 2021

BUY
$221.91 - $258.6 $29,070 - $33,876
131 Added 8.91%
1,602 $399,000
Q4 2020

Feb 09, 2021

BUY
$216.38 - $257.67 $17,310 - $20,613
80 Added 5.75%
1,471 $338,000
Q3 2020

Nov 12, 2020

BUY
$234.65 - $260.95 $5,631 - $6,262
24 Added 1.76%
1,391 $354,000
Q2 2020

Aug 06, 2020

BUY
$197.81 - $242.74 $113,542 - $139,332
574 Added 72.38%
1,367 $322,000
Q1 2020

May 11, 2020

BUY
$182.24 - $241.7 $7,836 - $10,393
43 Added 5.73%
793 $161,000
Q4 2019

Feb 14, 2020

BUY
$189.21 - $243.2 $141,907 - $182,400
750 New
750 $181,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Center For Financial Planning, Inc. Portfolio

Follow Center For Financial Planning, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center For Financial Planning, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Center For Financial Planning, Inc. with notifications on news.